Santos David A 4

What Happened
David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals (RIGL), had a performance-based stock option covering 7,394 shares reported as acquired (derivative) on June 17, 2026. The option carries an exercise price of $22.49 per share (the closing price on the original grant date), meaning it would cost roughly $166,291 to exercise all options. The filing reports the acquisition at $0.00 because this Form 4 records the vesting/award event (not an exercise or cash purchase).

Key Details

• Transaction date: June 17, 2026; Form 4 filed June 22, 2026.
• Reported transaction: Award/Acquisition (derivative) of 7,394 shares at $0.00.
• Option exercise price: $22.49 per share (total exercise cost ≈ $166,291).
• Footnotes: Option was originally granted Jan 29, 2025 with a performance-based vesting condition; the performance metric was satisfied and the option fully vested on June 17, 2026.
• Shares owned after transaction: Not disclosed in the provided Form 4.

Context

• This filing documents vesting of a performance-based option (a derivative award), not an immediate cash purchase or sale of shares. Santos has the right to exercise the options at $22.49 per share going forward; exercising, selling, or holding would trigger separate filings.
• Vesting awards are routine compensation events and do not by themselves indicate whether the insider will buy or sell shares.